In addition, YBX3 controls amino acid levels by influencing mRNA abundance of SLC7A5 and SLC3A2 [42], and as immunometabolism has been implicated in the function of various immune cells including DCs [44], YBX3 may contribute to the pathogenesis of BS by altering the function of DCs and is a potential therapeutic target. This evidence concerns the gene SLC7A5 and Bloom syndrome.